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Summary
Background The need for multiple clinical visits remains a barrier to women accessing safe legal medical abortion 
services. Alternatives to routine clinic follow-up visits have not been assessed in rural low-resource settings. We 
compared the eﬀ ectiveness of standard clinic follow-up versus home assessment of outcome of medical abortion in a 
low-resource setting.
Methods This randomised, controlled, non-inferiority trial was done in six health centres (three rural, three urban) in 
Rajasthan, India. Women seeking early medical abortion up to 9 weeks of gestation were randomly assigned (1:1) to 
either routine clinic follow-up or self-assessment at home. Randomisation was done with a computer-generated 
randomisation sequence, with a block size of six. The study was not blinded. Women in the home-assessment group 
were advised to use a pictorial instruction sheet and take a low-sensitivity urine pregnancy test at home, 10–14 days 
after intake of mifepristone, and were contacted by a home visit or telephone call to record the outcome of the 
abortion. The primary (non-inferiority) outcome was complete abortion without continuing pregnancy or need for 
surgical evacuation or additional mifepristone and misoprostol. The non-inferiority margin for the risk diﬀ erence 
was 5%. All participants with a reported primary outcome and who followed the clinical protocol were included in the 
analysis. This study is registered with ClinicalTrials.gov, number NCT01827995.
Findings Between April 23, 2013, and May 15, 2014, 731 women were recruited and assigned to clinic follow-up 
(n=366) or home assessment (n=365), of whom 700 were analysed for the main outcomes (n=336 and n=364, 
respectively). Complete abortion without continuing pregnancy, surgical intervention, or additional mifepristone and 
misoprostol was reported in 313 (93%) of 336 women in the clinic follow-up group and 347 (95%) of 364 women in 
the home-assessment group (diﬀ erence –2·2%, 95% CI –5·9 to 1·6). One case of haemorrhage occurred in each 
group (rate of adverse events 0·3% in each group); no other adverse events were noted.
Interpretation Home assessment of medical abortion outcome with a low-sensitivity urine pregnancy test is 
non-inferior to clinic follow-up, and could be introduced instead of a clinic follow-up visit in a low-resource setting.
Funding Swedish Research Council and Swedish International Development Agency.
Copyright © Iyengar et al. Open Access article published under the terms of CC BY.
Introduction
Early ﬁ rst trimester medical abortion has been recognised 
as a safe and eﬀ ective method for induced termination of 
pregnancy;1,2 however, it remains inaccessible for many 
women in low-resource settings. Reduced access to safe 
abortion leads women to seek unsafe abortion, an 
important cause of maternal mortality worldwide.3 In 
India, 8% of maternal deaths result from unsafe abortion; 
this proportion is slightly higher (10%) in the group of 
states that includes Rajasthan.4 An important factor 
aﬀ ecting access and acceptability of medical abortion in 
women is the number of required clinical visits.5,6 The 
need for a routine follow-up visit to a clinic can be 
especially burdensome for women with low autonomy 
and limited ﬁ nancial resources, which is often the 
situation in low-resource settings. Furthermore, long 
travel time can result in lost wages and diﬃ  culties in 
ensuring privacy. Yet several clinical guidelines for 
medical abortion require women to return for a follow-
up visit.7,8
Since women with post-abortion complications, if 
properly counselled, seek care before the routine follow-
up visit,9 the main purpose of a routine follow-up visit 
after medical abortion is to detect a continuing 
pregnancy. Continuing pregnancies occur in 0·5–1·1% 
of women after ﬁ rst trimester medical abortion with 
mifepristone and misoprostol.10,11 A systematic review 
concluded that alternatives to routine in-person follow-
up visits after medical abortion are accurate in 
diagnosing continuing pregnancies.12 Technical and 
policy guidelines published by WHO recommend that 
there is no medical need for a routine clinic follow-up 
visit after medical abortion with mifepristone and 
misoprostol.2 However, the quality of evidence 
underlying this recommendation is low and is mainly 
based on observational studies.
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In recent years, studies have assessed alternative 
methods of follow-up after medical abortion, such as use 
of a low-sensitivity urine pregnancy test, semiquantitative 
urine pregnancy test, or a high-sensitivity pregnancy test 
by women at home with follow-up by telephone call, text 
message, or online.13–21 These studies are mainly from 
high-resource settings, and depend on women having 
access to a telephone or the internet, and the ability to 
read. However, the situation in low-resource settings is 
diﬀ erent: large numbers of women reside in rural areas, 
have a low literacy level, and have limited access to 
telephone and transport facilities. Furthermore, there is 
no evidence to show that women with low literacy levels 
can take and interpret a pregnancy test at home.
The aim of this trial was to assess whether an approach 
of home assessment of medical abortion outcome is as 
eﬀ ective in detecting ongoing pregnancy as a clinic 
follow-up visit in a low-resource setting.
Methods
Study design and participants
This study was a randomised, controlled, non-inferiority 
trial to assess the outcome of medical abortion with two 
methods of follow-up: routine clinic follow-up and self-
assessment at home. The trial followed the CONSORT 
guidelines for non-inferiority randomised trials.22 The 
study protocol of this trial describes the methods in 
detail.23 Women with unwanted pregnancies opting for 
medical abortion were eligible to participate in the study 
if their gestational age was 9 weeks or less as estimated 
by bimanual pelvic examination, if they resided in an 
area where follow-up was possible or they had access to a 
telephone on which they could talk privately, and who 
agreed to a follow-up after 2 weeks, by either telephone 
or home visit. A woman was ineligible if she had any 
contraindication to medical abortion, was younger than 
18 years, or had a haemoglobin concentration of less than 
85 g/L.
The study was done in three rural and three urban 
health centres in two districts of Rajasthan state in India. 
Of these, all three rural and one urban health centre were 
operated by a non-proﬁ t organisation, whereas two urban 
clinics were operated by single private doctors. The rural 
health centres were health facilities located 20–50 km 
from the district headquarters. All study clinics provided 
a range of reproductive health services, and specialists in 
obstetrics and gynaecology provided the abortion services 
in all clinics. In the state of Rajasthan, 75% of the 
population is rural, 48% of women are literate,24 and an 
estimated 36% of women have the autonomy to travel 
alone.25 In the study districts, 46% of people belong to 
underprivileged scheduled tribes or castes, and 30% of 
households owned a mobile telephone in 2007–08.26
The study was approved by the institutional ethics 
committee of Action Research and Training for Health, 
Udaipur, India, and the regional ethics committee at 
Karolinska Institutet, Stockholm, Sweden. All women 
gave written informed consent. Women were recruited 
between April 23, 2013, and May 15, 2014. The main 
outcome was measured 30 days after recruitment. One 
interim analysis was done halfway through the enrolment 
period and safety and eﬃ  cacy was reviewed by a data and 
safety monitoring board.
Randomisation and masking
All eligible women who consented to participate in the 
study were randomly assigned (1:1) to one of two groups 
by a research assistant: clinic follow-up or home 
assessment. Randomisation was done with a computer-
generated randomisation sequence, with a block size of 
six. The sequence was generated at the coordinating 
centre based in Udaipur, India. Sealed opaque envelopes 
containing the random allocation were numbered 
consecutively by an independent staﬀ  member at Udaipur, 
and were sent to the study sites. To avoid bias by clinical 
staﬀ , randomisation was done after a decision was taken 
regarding place of misoprostol use (ie, at home or in the 
clinic). At each facility, research assistants were responsible 
for opening the envelopes and allocation of patients. 
Blinding of the groups from research assistants and 
clinical staﬀ  was not possible, since they were involved in 
instructing women about method of follow-up.
Procedures
All women with an unwanted pregnancy were ﬁ rst seen 
by doctors to assess their eligibility for medical abortion 
in terms of gestational age and contraindications. 
Women received routine counselling on method of 
abortion and contraception, and for women opting for 
medical abortion, a decision was made regarding place of 
misoprostol administration. Providers made a judgment 
regarding the place for misoprostol administration on 
the basis of their clinic’s standard procedure and the 
woman’s ability to reach a clinic within a reasonable time 
in the event of a complication. In cases in which there 
were no concerns, women were free to choose where to 
use misoprostol according to their preference. Providers 
at all sites followed their standard clinical procedures for 
medical abortion and no changes were made for the 
purpose of the study. Ultrasonography was not routinely 
used in ﬁ ve of the six study centres. The gestational age 
was estimated on the basis of bimanual examination by 
clinicians. After receiving mifepristone orally (200 mg), 
women were given instructions regarding the use of 
misoprostol (800 mcg, to be used 2 days later). The route 
of misoprostol administration diﬀ ered across clinics as 
per their standard protocols and was sublingual (55%), 
vaginal (17%), or oral (28%). 
Women in the clinic follow-up group were instructed to 
return for a visit 10–14 days after intake of mifepristone 
for clinical examination, and were oﬀ ered a travel 
reimbursement (roughly US$3·3). A doctor or nurse 
assessed the abortion outcome, did a low-sensitivity 
urine pregnancy test (Vedalab, Alençon, France; with a 
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serum human chorionic gonadotropin cutoﬀ  of 
1000 IU/mL), and research assistants subsequently 
undertook the follow-up interviews.
Women in the home-assessment group were provided 
with a low-sensitivity urine pregnancy test to be done 
10–14 days after the intake of mifepristone. They also 
received a pictorial instruction sheet (ﬁ gure 1) with 
instructions on taking and interpreting the test, 
symptoms indicative of complications, and contact 
details of study clinics. Women were provided with 
detailed instructions verbally at the clinic on the use of 
the pregnancy test and were asked to return if they had 
any health problems or a positive or unclear test result. 
Follow-up interviews of women in the home-assessment 
group were done by home visits or a telephone call on 
day 12–15 after mifepristone, to screen for continuing 
pregnancies and complications. Some women who 
lacked privacy at home opted to come to the clinic after 
home assessment to report the outcome of their abortion 
and the result of the pregnancy test. Three attempts were 
made to contact women, up to 30 days after intake of 
mifepristone, after which they were considered lost to 
scheduled follow-up. Strict attention was paid to 
conﬁ dentiality during home visits and telephone calls.22 
Women who reported the outcome of pregnancy tests as 
positive or “not sure”, or who had symptoms suggestive 
of complications, were referred to the clinic. If the 
woman had not done the pregnancy test by the time of 
the follow-up interview, the research assistant reminded 
her to do the test and interpret the result herself.
Women detected to have a continuing pregnancy or 
incomplete abortion received surgical evacuation or 
additional mifepristone and misoprostol. Clinical records 
of all women presenting for interim visits (deﬁ ned as visits 
by women between the day of misoprostol administration 
and scheduled follow-up contact at the clinic or by the 
research assistant) were checked to record the outcome of 
abortions and the procedures performed. Women in the 
clinic follow-up group who did not return for their follow-
up visit or women in the home-assessment group who had 
a positive or “not sure” pregnancy test but did not return to 
the clinic, were later contacted by the research assistants by 
telephone call or home visit. Information was gathered on 
return of menses, continuing pregnancy, any surgical 
intervention, treatment for completion of abortion at 
another clinic, or complications (hospital admission, 
intravenous ﬂ uids, blood transfusion).
Outcomes
The primary outcome measure was eﬃ  cacy, deﬁ ned as 
complete abortion without continuing pregnancy or the 
need for surgical intervention or additional mifepristone 
Figure 1: Pictorial instruction sheet
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and misoprostol. Secondary outcomes were safety 
(deﬁ ned as no adverse events requiring hospital 
admission, blood transfusion, intravenous ﬂ uids, or 
intravenous antibiotics) and feasibility (deﬁ ned as ability 
of women to take the low-sensitivity urine pregnancy test 
on their own, to determine the outcome of abortion). The 
outcomes were measured by questionnaires administered 
at follow-up. Clinical records were reviewed for women 
who made interim visits. Additionally, we compared 
reasons for interim visits between groups.
Statistical analysis
To test the hypothesis that home assessment of outcome 
of abortion would be as eﬀ ective as clinic follow-up, we set 
the margin of non-inferiority to an absolute diﬀ erence 
between groups of ﬁ ve percentage points in the rate of 
unsuccessful abortions. The rate of complete abortion 
with mifepristone and misoprostol reported in practice is 
95%,11 and we based this cutoﬀ  on what we deemed to be a 
clinically important diﬀ erence and on ethical criteria, cost, 
and feasibility. Hence, we aimed to prove that the rate of 
complete abortion is at most 5% lower in the home-
assessment group than in the routine follow-up group.
On the assumption that 5% of women would have 
unsuccessful abortions (continuing pregnancies or 
incomplete abortions) after medical abortion with 
routine follow-up,11 a sample size of 596 women was 
calculated to be suﬃ  cient (with a two-sided 95% CI and 
80% power) to establish non-inferiority of the 
intervention. We allowed for 20% loss to follow-up, and 
planned to recruit 716 women.
Data entry was done at the coordinating centre in 
India. All statistical calculations were made with SPSS 
(version 22) and in R (version 3.0.3). Categorical variables 
are presented with descriptive statistics and were 
compared with χ² tests. Continuous data were presented 
as mean (SD) and compared with t tests. p values less 
than 0·05 were considered statistically signiﬁ cant.
We identiﬁ ed two study populations: the intention-to-
treat (ITT) population (all randomly assigned women as 
per the randomisation list, irrespective of actual 
allocation) and evaluable participants (those actually 
allocated to the study groups, with a reported primary 
outcome, and who followed the clinical protocol). Hence, 
the evaluable population consisted of all women who 
took mifepristone and misoprostol, and for whom 
outcome information was available either through 
scheduled follow-up contacts, through later contacts, or 
through records of interim visits. Our analysis and 
interpretation of the primary outcome is based on the 
evaluable population.
Since information about the primary outcome was 
missing for 18 women in the ITT population, we did two 
sensitivity analyses in which the missing values were 
imputed: one assuming that all women with missing 
values had successful abortions and one assuming that 
all women with missing values had unsuccessful 
abortions. This study is registered with ClinicalTrials.gov, 
number NCT01827995.
Role of the funding source
The funders of the study were not involved in study 
design, data collection, data analysis, data interpretation, 
or writing of the report. All authors had full access to the 
data in the study. The corresponding author had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Figure 2 shows the trial proﬁ le. 731 eligible women 
consented and were randomly assigned to clinic follow-
up (n=366) or home assessment (n=365). At the time of 
analysis, we detected that 15 women in the clinic follow-
up group as per the randomisation list were allocated to 
the home assessment group, and two women in the 
home assessment group as per the randomisation list 
were allocated to the clinic follow-up group because of an 
error in randomisation by research assistants. However, 
comparison of results between the two groups as per 
randomisation list did not show any signiﬁ cant 
diﬀ erences in characteristics or outcomes (table 1). Most 
women (73%) lived in a rural area, 56% belonged to 
scheduled castes or tribes, and 45% were literate.  
Figure 2: Trial proﬁ le
*15 women who were in the clinic follow-up group as per the randomisation list received home assessment, and 
two women who were in the home-assessment group as per the randomisation list received clinic follow-up. 
957 women assessed for eligibility
731 randomly assigned
366 assigned to clinic follow-up* 365 assigned to home assessment*
366 eligible for analysis in ITT population 365 eligible for analysis in ITT population
336 eligible for analysis of evaluable 
 participants*
364 eligible for analysis of evaluable 
 participants*
737 eligible for randomisation
6 declined to participate
220 excluded
 95 gestation >9 weeks
 9 haemoglobin <85 g/L
 3 younger than 18 years
 105 lived outside field area
 8 did not want follow-up
11 lost to follow-up (primary 
 outcome not available)
7 lost to follow-up (primary outcome 
 not available)
6 excluded because of protocol 
 violation
7 excluded because of protocol 
 violation
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Adherence to scheduled follow-up contact was lower in 
the clinic follow-up group (274 [78%]) than in the home-
assessment group (349 [92%]; table 2). In the home-
assessment group, 267 (77%) women were followed up 
by home visits, 65 (19%) by telephone calls, and 17 (5%) 
by clinic visit. 128 women made an interim visit, and of 
these, clinical outcomes were determined for 110 women. 
Of the women who had neither a scheduled follow-up 
contact nor an interim visit, outcome information was 
obtained for 70 women by home visits or telephone calls. 
13 women (six in the clinic follow-up group and seven in 
the home-assessment group) did not use misoprostol 
and were excluded from the analysis, and 18 women 
(11 in the clinic follow-up group and seven in the home-
assessment group) were lost to follow-up (ﬁ gure 2). 
700 women (clinic follow-up, n=336; home assessment, 
n=364) were therefore evaluable and included in the 
analysis of the primary outcome.
In the analysis of evaluable participants, complete 
abortion was reported in 313 (93%) of 336 women in the 
clinic follow-up group and 347 (95%) of 364 women in 
the home-assessment group (risk diﬀ erence –2·2%, 
95% CI –5·9 to 1·6; table 3, appendix). In the ITT 
Clinic follow-up 
group (n=353)
Home-assessment 
group (n=378)
Mean age (years) 27·22 (4·9) 26·98 (4·78)
Residence
Urban 100 (28%) 99 (26%)
Rural 253 (72%) 279 (74%)
Caste
Scheduled tribes or castes 192 (54%) 218 (58%)
Others 161 (46%) 160 (42%)
Level of education
No formal education 183 (52%) 222 (59%)
Lower than primary 61 (17%) 52 (14%)
Primary 68 (19%) 59 (16%)
Secondary or above 41 (12%) 45 (12%)
Paid employment
Yes (daily wages/salaried/
business/other)
59 (17%) 74 (20%)
No (housewife/farmer) 294 (83%) 304 (80%)
Ownership of telephone
Self 164 (46%) 160 (42%)
Husband 123 (35%) 146 (39%)
Other family members or none 66 (19%) 72 (19%)
Gestational age (weeks)
<6 67 (19%) 61 (16%)
6–7 194 (55%) 213 (56%)
8–9 92 (26%) 104 (28%) 
Previous births
0 16 (5%) 20 (5%)
1–2 201 (57%) 212 (56%)
3 or above 136 (39%) 146 (39%)
Previous induced abortion 121 (34%) 116 (31%)
Type of previous induced abortion*
Previous medical abortion 90 (25%) 92 (24%)
Previous surgical abortion 36 (10%) 29 (8%)
Place of misoprostol use
Home 170 (48%) 172 (46%)
Clinic 183 (52%) 206 (54%)
Data are mean (SD) or n (%). *Some women reported several types of abortion. 
Table 1: Background characteristics as per study group allocation
Clinic follow-up 
group (n=353)
Home-assessment 
group (n=378)
Number having scheduled follow-up contact 274 (78%) 349 (92%)
Number who did not use misoprostol or were lost to follow-up 17 (5%) 14 (4%)
Evaluable population* 336 (95%) 364 (96%)
Method of outcome determination in evaluable participants
Interim visits† 48 (14%) 62 (17%)
Scheduled follow-up contacts 232 (69%) 288 (79%)
Later contacts for outcome information 56 (17%) 14 (4%)
*Number of women who used misoprostol and whose outcome information is available. †Apart from seven women 
(six in clinic follow-up group and one in the home assessment group), all other women with interim visits also had a 
scheduled follow-up contact. 
Table 2: Adherence to trial procedures and mode of outcome determination
Clinic follow-up 
group
Home-assessment 
group
Diﬀ erence in outcome 
rates (95% CI)
ITT analysis* 366 365 ..
Complete abortion 340 (93%) 347 (95%) –2·2% (–5·9% to 1·5%)
Unsuccessful abortion 26 (7%) 18 (5%) ..
Continuing† 7 (2%) 3 (1%) ..
Continued the pregnancy 3 1 ..
Surgical evacuation 3 2 ..
Repeat medical abortion 1 0 ..
Incomplete‡ 19 (5%) 15 (4%) ..
Surgical evacuation 15 12 ..
Repeat misoprostol 4 3 ..
Evaluable population analysis§ 336 364 ..
Complete abortion 313 (93%) 347 (95%) –2·2% (–5·9 to 1·6%)
Unsuccessful abortion 23 (7%) 17 (5%) ..
Continuing 5 (1%) 2 (1%) ..
Continued the pregnancy 1 0 ..
Surgical evacuation 3 2 ..
Repeat medical abortion 1 0 ..
Incomplete‡ 18 (5%) 15 (4%) ..
Surgical evacuation 14 12 ..
Repeat misoprostol 4 3 ..
Lost to follow-up 11 7 ..
Violation of protocol 6 7 ..
Data are number of women or n (%), unless otherwise stated. *For the intention-to-treat (ITT) analysis, the groups 
were analysed as per the randomisation list and with imputed success where outcome was unknown. †The three 
additional continuing pregnancies in the ITT analysis were in women who did not use misoprostol, hence these were 
protocol violations. ‡Incomplete abortions were deﬁ ned as diagnosis of retained products of conception with need for 
surgical intervention or additional misoprostol. §For the evaluable population analysis, the groups were analysed as 
per actual allocation. 
Table 3: Outcome of medical abortion for intention-to-treat population and evaluable population
See Online for appendix
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population, when success was imputed for unknown 
outcomes, complete abortion was reported in 340 (93%) 
of 366 women in the clinic follow-up group and 347 
(95%) of 365 in the home-assessment group (risk 
diﬀ erence –2·2%, 95% CI –5·9 to 1·5). For the primary 
outcome, the upper limit of the 95% CI lies within the 
non-inferiority margin (5%) for both ITT and evaluable 
population analyses.
The sensitivity analysis for the ITT population did not 
alter the results when imputing failure (data not shown). 
In the analysis with adjustment for caste, residence, 
education, employment, and place of misoprostol use, 
there was no diﬀ erence in the rate of complete abortion 
between clinic follow-up and home-assessment groups. 
However, complete abortions were correlated with 
residence in a rural area and belonging to scheduled 
tribes or castes (data not shown).
In the ITT population, there were seven continuing 
pregnancies in the clinic follow-up group and three in 
the home-assessment group; in the evaluable population, 
there were ﬁ ve and two continuing pregnancies, 
respectively. After imputation of a complete abortion 
outcome to all women who were lost to follow-up, the 
overall ITT complete abortion rate was 94% and 
continuing pregnancy rate was 1%. In the analysis of 
evaluable participants, the overall rates of complete 
abortion, incomplete abortion, and continuing pregnancy 
were 94%, 5%, and 1%, respectively (table 3). Of the 
seven continuing pregnancies in the evaluable 
population, four were detected by interim visits on day 6 
or later, whereas three were detected by scheduled visits 
(table 4). 22 (7%) women in the clinic follow-up group 
and 17 (5%) women in the home-assessment group had 
surgical intervention or additional mifepristone or 
misoprostol or both; however, the diﬀ erence between 
groups was not statistically signiﬁ cant.
One woman in the clinic follow-up group needed blood 
transfusion and admission to hospital for haemorrhage, 
and one woman in the home-assessment group needed 
intravenous ﬂ uids for haemorrhage. Overall, the rate of 
adverse events in our study was 0·3% (table 5). 95 (15%) of 
619 women who had a scheduled follow-up reported other 
side-eﬀ ects (heavy bleeding, severe abdominal pain, fever, 
or feeling unwell). Of 128 women who sought care at 
interim visits, nearly half (n=62) visited because of a 
symptom suggestive of an abortion complication 
(appendix); the remaining interim visits were related to 
contraception or to concerns about completion of abortion. 
Most interim visits occurred between the day of 
misoprostol administration and scheduled follow-up 
contact (between days 4 and 14 [116 (91%)]).
Of the 289 women in the home-assessment group 
whose outcome was not identiﬁ ed by an interim visit, 
233 (81%) took their low-sensitivity urine pregnancy test 
before being contacted by the research assistant, 54 (19%) 
did it after being reminded by the research assistant, and 
two women (1%) did not do the test (table 6). Most of the 
women who took the test after being reminded by the 
research assistant interpreted the result themselves. 15 
(5%) women who took the pregnancy test had a positive 
result or were unsure of their result, and were asked to 
return to the clinic. Among the 11 women who returned to 
the clinic, there was one continuing pregnancy and three 
incomplete abortions. Of 272 women with a negative test 
result, 25 had some concerns or symptoms suggestive of 
complications, and were advised to return to the clinic. 
Ten of these women complied with the advice and 
returned to the clinic and one was diagnosed as having 
incomplete abortion. Women who did not do the low-
sensitivity urine pregnancy test or who had a positive or 
“not sure” test result, and did not return to the clinic, were 
subsequently contacted and all reported complete 
abortions. 229 (98%) women who did the test on their 
own reported that it was easy to use. Women were less 
likely to take the test if they had reported a side-eﬀ ect 
(20/ 33 [61%]) versus if they had not reported a side-eﬀ ect 
(213/256 [83%]); lived in a rural area (162/211 [77%]) versus 
urban area (71/78 [91%]); belonged to a scheduled tribe or 
caste (123/165 [75%]) versus those belonging to other 
Clinic follow-up 
group (n=336)
Home-assessment 
group (n=364)
Ongoing pregnancy 5 (1%) 2 (1%)
Interim visit 3 (1%) 1 (<1%)
Scheduled visit to the clinic 2 (1%) 1 (<1%)
Incomplete abortion 18 (5%) 15 (4%)
Interim visit 10 (3%) 11 (3%)
Scheduled visit to the clinic 8 (2%) 4 (1%)
All unsuccessful abortions 23 (7%) 17 (5%)
Interim visit 13 (4%) 12 (3%)
Scheduled visit to the clinic 10 (3%) 5 (1%)
Data are n (%).
Table 4: Timing of outcome determination
Clinic follow-up 
group (n=336)
Home-assessment 
group (n=364)
Serious adverse events
Haemorrhage requiring intravenous ﬂ uids 1 (<1%) 1 (<1%)
Haemorrhage requiring blood transfusion 1 (<1%) 0
Infection requiring intravenous antibiotics 0 0
Hospital admission 1 (<1%) 0
Side-eﬀ ect reported to follow-up contact* 274 349
Any side-eﬀ ect reported to follow-up contact 
(multiple responses possible)
47 (17%) 49 (14%)
Excessive bleeding 9 (3%) 24 (7%)
Severe abdominal pain 12 (4%) 19 (5%)
Feels unwell 14 (5%) 13 (4%)
Had fever 24 (9%) 19 (5%)
Data are number or n (%). *Information about side-eﬀ ects is available for 619 women who had a scheduled contact.
Table 5: Adverse events and side-eﬀ ects
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castes (110/124 [89%]), and were illiterate (121/157 [77%]) 
versus literate (112/132 [85%]). Most women in the clinic 
follow-up group (262/274 [96%]) and home-assessment 
group (334/349 [96%]) were satisﬁ ed with the method of 
abortion follow-up.
In the 515 women from both groups who were 
successfully contacted, whose abortion outcome was not 
determined by interim visits, and whose pregnancy tests 
were done, two continuing pregnancies and no false-
negative tests were identiﬁ ed. Hence the sensitivity of 
the low-sensitivity urine pregnancy test to detect 
continuing pregnancy was 100% (95% CI 19·7–100) 
and speciﬁ city was 94·5% (92·1–96·2). The negative and 
positive predictive values were 100% (99·0–100) and 6·7% 
(1·2–23·5), respectively.
Discussion
Our ﬁ ndings suggest that home assessment with a low-
sensitivity urine pregnancy test is an eﬀ ective alternative 
to clinic follow-up after early medical abortion, and that 
women can take and interpret a low-sensitivity pregnancy 
test even in low-resource settings. Although our study 
was not powered to establish safety of home assessment, 
it shows a very low rate of adverse events in line with 
previous studies that have reported rates of between 
0·11% and 0·16%.27,28 Thus, we infer that home 
assessment is an eﬀ ective and safe alternative to clinic 
follow-up after early medical abortion. Two other 
randomised controlled trials have compared self-
assessment with clinic follow-up visits. However, there 
are important contextual diﬀ erences between these trials 
and ours: the trial in Vietnam recruited only women who 
were literate, able to complete an at-home symptom 
checklist, and who had a personal telephone. Further, it 
used a semiquantitative pregnancy test followed up with 
a telephone call.19 Similarly, in a trial from Europe that 
used the same low-sensitivity urine pregnancy test with a 
1000 IU/L cutoﬀ  for self-assessment, women were 
followed up by telephone call, were educated, and their 
gestational age was identiﬁ ed by ultrasound.16 In our 
study, more than half the participants were illiterate and 
did not own a telephone, and most of the women in the 
home-assessment group were followed up with a home 
visit. Despite these diﬀ erences, our ﬁ ndings correspond 
well with previous trials showing that self-assessment 
was non-inferior to clinic follow-up and is as feasible in 
these settings.
In our study, fewer continuing pregnancies were 
detected in the home-assessment group than in the clinic 
follow-up group. However, we believe that this diﬀ erence 
was by chance and not because we missed any continuing 
pregnancies, since the overall loss to follow-up was very 
low (2·5%) in the whole study, and even lower in the 
home-assessment group (1·9%). Furthermore, more 
incomplete abortions were detected in the clinic follow-
up group than in the home-assessment group at 
scheduled follow-up. The diﬀ erence was not statistically 
signiﬁ cant but indicates a trend, and could result from 
providers’ greater propensity to intervene during clinic 
visits. A study concluded that the diﬀ erences in surgical 
intervention rates after medical abortion are likely to be 
caused by diﬀ erent clinical practices and local guidelines, 
rather than genuine need for surgical intervention.29 
Thus, a scheme based on home assessment is likely to 
prevent the unnecessary surgical interventions and 
ultrasounds that might be done at clinic follow-up visits.
In our study, about two-thirds of unsuccessful abortions 
were detected by interim visits. Other studies have also 
shown that complications and incomplete abortions rarely 
occur at the time of scheduled follow-up visits and call for 
unscheduled visits.9 However, the reliance on symptoms 
alone has not been shown to be a precise method of 
follow-up after medical abortion,12 hence an objective 
measure to detect continuing pregnancies is still needed.
We chose to use a low-sensitivity urine pregnancy test 
with a 1000 IU/L cutoﬀ  in this study because it has been 
shown to be eﬀ ective in previous studies,14,15 and is a 
Number of women 
(n=289)*
Did LSUP test on her own without reminder 233 (81%)
Ease of doing the LSUP test (in women who did it without reminder)
Easy 229 (98%)
Diﬃ  cult 4 (2%)
Reasons for not doing the LSUP test on her own
Forgot, was planning to do it in a day or two, or 
was waiting for research assistant
18 (32%)
Diﬃ  cult to do or no privacy 18 (32%)
Went out of house (to attend a social function or 
to parents’ home) or lost LSUP card
7 (13%)
Did not think it was needed 4 (7%)
Bleeding continued or ill 8 (14%)
Did LSUP test after reminder by research assistant 54 (19%)
Did not do LSUP test at all 2 (1%)
Woman looked at pictorial instruction sheet 225 (78%)
Result of LSUP test (n=287)
Positive 12 (4%)
Not sure 3 (1%)
Negative 272 (95%)
Referred to the clinic by research assistant
Yes 40 (14%)
No 249 (86%)
Women who screened positive on LSUP test and referred to the clinic (n=15)
Returned to the clinic 11/15 (73%)
Did not return to the clinic 4/15 (27%)
Women who screened negative on LSUP test or did not do the LSUP test and 
referred to the clinic (n=25)
Returned to the clinic 10/25 (40%)
Did not return to the clinic 15/25 (60%)
Data are n (%). LSUP=low-sensitivity urine pregnancy. *Data exclude all women 
whose abortion outcome was determined on interim visits. 
Table 6: Characteristics of home-assessment group
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simple test with two columns, which is likely to be better 
interpreted by women with low literacy than the 
semiquantitative pregnancy test, which has ﬁ ve columns. 
Use of a high-sensitivity pregnancy test at 1 month would 
delay the detection of continuing pregnancies and in the 
event of a continuing pregnancy, women would ﬁ nd it 
diﬃ  cult to obtain abortion service in a primary care 
setting. In our study, 80% of women did the pregnancy 
test on their own, and nearly all found it easy to do. Our 
ﬁ nding that more than three-quarters of rural and 
illiterate women were able to do their low-sensitivity 
urine pregnancy test suggests that home assessment is 
feasible even in low-literacy rural settings. Discussions 
with our team showed that the design of the study 
protocol, in which all women were informed that a 
research assistant would visit them, might have led some 
of the women to think that they were meant to wait for 
this visit before taking the pregnancy test. We expect that 
if this intervention is implemented in the health system, 
a greater proportion of women will do the test without 
need for the reminder.
Women in low-resource settings may especially beneﬁ t 
from home assessment, since their autonomy to travel is 
low, ﬁ nancial resources are meagre, and transport 
options are scarce and time consuming. The need for 
multiple clinic visits might raise concerns about privacy, 
child care, and lost wages, and may deter women from 
seeking safe abortion services. Home assessment 
enabled 75% of women to avoid a clinic visit, and hence 
introduction of a system of home assessment could lead 
to substantial reductions in the costs of clinic follow-up 
visits for women and health systems. Furthermore, since 
clinic follow-up rates after medical abortion tend to be 
low anyway,9 home assessment would allow a greater 
proportion of women to determine their abortion 
outcome. Allowing home assessment would give women 
greater autonomy in managing the abortion process, 
seeking care only when needed and still allowing them to 
know their abortion outcome. Furthermore, we suggest 
that, irrespective of the system of follow-up, counselling 
on danger signs and symptoms suggestive of continuing 
pregnancy should be routinely provided on the day of 
mifepristone intake.
The external validity and applicability of the ﬁ ndings of 
our study are very high. The socioeconomic and 
demographic characteristics of study participants 
represent women living in underserved areas of the 
country and reﬂ ect the composition of the general 
population in this area. Additionally, the rural health 
centres were small health facilities located in remote 
areas, whereas the urban health centres were single 
provider operated clinics, representative of typical health 
facilities providing abortion services.
The introduction of a system of home assessment as a 
replacement for routine clinic follow-up can be explored 
in health systems. The scheme of home assessment 
would mean that women are supplied with low-sensitivity 
urine pregnancy test kits, containers for collecting urine, 
and pictorial instruction sheets, on the day of 
mifepristone intake. Furthermore, providers assisting 
with abortion care need to counsel the women on how to 
take and interpret the test, and seek care for 
complications—this task can be done by existing mid-
level providers or by non-medical staﬀ  in health facilities. 
Additionally, the provider time spent on routine clinic 
follow-up visits would be saved. Some studies have used 
follow-up by telephone call with a symptom checklist 
along with self-assessment with a low-sensitivity or high-
sensitivity pregnancy test.14,15,18–20 However, in our setting, 
most women do not own a telephone and hence 
telephonic interviews or reminders would not be feasible. 
Additionally, home visit by a health worker could raise 
serious conﬁ dentiality problems; therefore, home 
assessment by women themselves without follow-up by 
telephone call or home visit would be most appropriate 
in the current scenario.
The low-sensitivity urine pregnancy test has a high 
negative predictive value for detection of continuing 
pregnancies, and hence the risk of missing a continuing 
pregnancy is extremely low. Although some women with 
a positive low-sensitivity urine pregnancy test despite a 
complete abortion would need to return to the clinic, it 
still diminishes the need for a clinic visit for most 
women. Currently, low-sensitivity urine pregnancy tests 
are commercially available in Europe, but not in other 
settings. These tests are not yet a part of routine abortion 
care; therefore, their development and production will 
have to be promoted by policy makers if they are 
recommended for follow-up after medical abortion. 
Experience with high-sensitivity pregnancy tests, which 
are widely available at low cost in India, shows that if low-
sensitivity pregnancy tests were to be widely promoted, 
Panel: Research in context
Systematic review
We searched Web of Science and PubMed between May 28, 2014, and Sept 5, 2014, with 
the search terms “medical abortion”, “induced abortion”, “follow up”, and “simpliﬁ ed” for 
studies and systematic reviews assessing follow-up after medical abortion. There were no 
language restrictions. We identiﬁ ed two randomised controlled trials16,19 and several 
observational studies 13–15,17,18,20,30 that have assessed alternative methods of follow-up. All 
these studies were either from high-resource settings or recruited women who were 
educated and had a personal telephone. The results of these studies show that alternative 
methods of follow-up after medical abortion are feasible and eﬀ ective to screen for 
continuing pregnancies.
Interpretation
Our study suggests that home assessment of outcome of abortion is non-inferior to clinic 
follow-up after early medical abortion. This study provides the only evidence thus far 
from a low-resource rural setting that women with low literacy can feasibly assess the 
outcome of an early medical abortion. Taken together, these studies provide evidence 
that service delivery guidelines on medical abortion should consider substituting a clinic 
follow-up visit with home assessment with an appropriate low-sensitivity urine 
pregnancy test and a user-friendly pictorial guide.
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produced, and marketed in low-resource countries, they 
could be introduced aﬀ ordably.
In conclusion, home assessment with a low-sensitivity 
pregnancy test is a feasible and eﬀ ective method to 
identify women with continuing pregnancy after early 
medical abortion, even for women living in remote areas 
of developing countries (panel). In areas where an 
additional visit to the clinic could deter women from 
seeking services from safe legal providers, reducing the 
need for a routine follow-up visit would increase access 
for women to safe abortion services, and contribute to a 
reduction in abortion-related maternal mortality.
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